What is the appropriate dosing, contraindications, and monitoring for prasugrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention?

Prasugrel in Acute Coronary Syndrome with PCI

Prasugrel should be administered with a 60 mg loading dose followed by 10 mg daily maintenance in ACS patients undergoing PCI, but is absolutely contraindicated in patients with prior stroke/TIA and generally should not be used in patients ≥75 years old or <60 kg body weight due to increased fatal bleeding risk. 1, 2

Dosing

Standard dosing:

• Loading dose: 60 mg orally 1, 2
• Maintenance dose: 10 mg once daily for patients ≥60 kg and age <75 years 1, 2
• Reduced maintenance dose: 5 mg once daily for patients <60 kg or age ≥75 years (use with extreme caution) 1, 2

Prasugrel should be taken with or without food and continued in combination with low-dose aspirin (75-100 mg daily) 1.

Absolute Contraindications

Do not use prasugrel in:

1. Prior stroke or transient ischemic attack - This is a Class III (Harm) recommendation because prasugrel causes worse net clinical outcomes including increased intracranial hemorrhage in this population 1, 3, 2
2. Active pathological bleeding 2
3. Hypersensitivity to prasugrel or any component 2

High-Risk Populations Requiring Extreme Caution

Age ≥75 years:

• Prasugrel is generally NOT recommended in patients ≥75 years due to increased risk of fatal and intracranial bleeding 2
• Exception: May consider in high-risk patients (diabetes mellitus or prior MI) where benefit may outweigh risk, but use reduced 5 mg maintenance dose 1, 2
• The TRITON-TIMI 38 trial showed no net benefit in this age group due to increased major bleeding 3, 4

Body weight <60 kg:

• Use reduced 5 mg maintenance dose 1, 2
• These patients have significantly higher bleeding rates (10.1% vs 4.2% in normal weight patients) 2

Clinical Indications

Prasugrel is Class I (should be administered) for:

• STEMI managed with primary PCI - to reduce MACE and stent thrombosis 1
• NSTE-ACS undergoing PCI - to reduce MACE and stent thrombosis 1

Prasugrel is preferred over clopidogrel (Class IIa recommendation) when:

• Patient has no history of stroke/TIA
• Patient is not at high risk for bleeding
• Patient is undergoing PCI for ACS 3

The TRITON-TIMI 38 trial demonstrated prasugrel reduced the primary endpoint (cardiovascular death, MI, or stroke) from 12.1% to 9.9% compared to clopidogrel (HR 0.81, p<0.001), with particularly dramatic reductions in stent thrombosis (2.4% to 1.1%) 4.

Bleeding Risk and Monitoring

Major bleeding rates:

• Non-CABG TIMI major bleeding: 2.2% with prasugrel vs 1.8% with clopidogrel 2
• Life-threatening bleeding: 1.4% vs 0.9% 2
• Fatal bleeding: 0.4% vs 0.1% (significantly higher with prasugrel) 2, 4

CABG-related bleeding:

• If urgent CABG is anticipated, do not start prasugrel 2
• Discontinue prasugrel at least 7 days before any planned surgery 2
• CABG-related major bleeding occurs in 11.3% with prasugrel vs 3.6% with clopidogrel 2

Additional bleeding risk factors to assess:

• Concomitant medications that increase bleeding (anticoagulants, NSAIDs, SSRIs) 2
• Propensity to bleed 2
• Recent or planned surgical procedures 2

Critical monitoring point: Suspect bleeding in any patient on prasugrel who becomes hypotensive, especially after invasive or surgical procedures 2. The highest bleeding risk occurs in the first 7 days after initiation (see bleeding curve data) 2.

Key Clinical Pitfalls

1. Never give prasugrel to stroke/TIA patients - This cannot be overstated; the harm is clear and consistent across trials 1, 3, 2

2. Do not prematurely discontinue - Stopping prasugrel increases risk of stent thrombosis, MI, and death 2. If bleeding occurs, manage bleeding without stopping prasugrel if possible 2

3. Avoid in patients likely to need urgent CABG - The drug effect persists for days and dramatically increases surgical bleeding 2

4. Consider clopidogrel instead when:

   • Age ≥75 years without high-risk features (diabetes/prior MI)
   • Weight <60 kg
   • Any stroke/TIA history
   • High bleeding risk from other factors
   • Prasugrel unavailable or not tolerated 1

5. Opioid interaction - Opioids decrease prasugrel absorption; consider parenteral antiplatelet agents in patients requiring ongoing opioid therapy 2

Rare but Serious Adverse Events

Thrombotic thrombocytopenic purpura (TTP) has been reported with prasugrel 2. Consider this diagnosis in patients developing thrombocytopenia with microangiopathic hemolytic anemia.

Hypersensitivity reactions including angioedema can occur, particularly in patients with prior hypersensitivity to other thienopyridines 2.